MARKET

TLSI

TLSI

TriSalus Life Sciences Inc.
NASDAQ
3.240
+0.090
+2.86%
After Hours: 3.300 +0.06 +1.85% 17:53 05/20 EDT
OPEN
3.140
PREV CLOSE
3.150
HIGH
3.290
LOW
3.020
VOLUME
355.66K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
2.200
MARKET CAP
198.99M
P/E (TTM)
-2.2975
1D
5D
1M
3M
1Y
5Y
1D
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
Barchart · 1d ago
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Barchart · 1d ago
Analysts’ Top Healthcare Picks: Compugen (CGEN), TriSalus Life Sciences (TLSI)
TipRanks · 1d ago
TriSalus Leaders Quietly Make a Bold Bet on the Company’s Future
TipRanks · 2d ago
TriSalus director Mats Wahlstrom buys 60,000 shares worth $151,800
PUBT · 2d ago
TriSalus director Michael P Stansky acquires common shares worth $1.53 million
PUBT · 2d ago
TriSalus CFO David Patience acquires 7,100 shares for $17,253
PUBT · 2d ago
TriSalus director Gary B. Gordon acquires 10,000 common shares for $24,600
PUBT · 2d ago
More
About TLSI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

Webull offers TriSalus Life Sciences Inc stock information, including NASDAQ: TLSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSI stock methods without spending real money on the virtual paper trading platform.